Arena Pharmaceuticals Reports Long-Term Data From Ongoing Open-Label Extension Of Phase 2 Trial Evaluating Ralinepag In Pulmonary Arterial Hypertension; DRalinepag Demonstrated Durable, Long-Term Improvements In PVR And 6MWD